Exact Sciences Q4 Revenues Slide 40 Percent, Cologuard Trial Progressing | GenomeWeb

The story has been updated to include comments from company officials during a conference call.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exact Sciences today reported a 40 percent drop year over year in fourth-quarter revenues, though its CEO said that the clinical trial for its colorectal cancer screening test "remains on track."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."